Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PiCCA Study of panitumumab plus cisplatin/gemcitabine in KRAS wild-type biliary tract cancer
2010-018850-11Phase 2Completed
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Dec 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer comparing Panitumumab + cisplatin + gemcitabine with Cisplatin + gemcitabine (2 arms). Primary endpoint: Progression-free survival rate at 6 months. Started Dec 2010; status: completed.
02
Drugs
panitumumabcisplatingemcitabine
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2010-018850-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018850-11.